Key result
Pharmacodynamic modeling predicted that twice daily of S-indobufen alone produces a greater anti-platelet effect than the S- and R-mixture formulation, with S-indobufen being more potent.
Why the study?
Does S-indobufen or R-indobufen differ in anti-platelet efficacy in plasma from healthy subjects?
Does S-indobufen or R-indobufen differ in anti-platelet efficacy in plasma from healthy subjects?
Answers are grounded in this paper and cite their sources.
Pharmacodynamic modeling suggests S-indobufen is more potent than R-indobufen for platelet inhibition, which may inform the development of enantioselective formulations.
Indobufen (Ibustrin), a reversible inhibitor of platelet aggregation, exists in two enantiomeric forms in 1:1 ratio. Here, we characterized the anti-platelet effect of S-and R-indobufen using response surface modeling using NONMEM and predicted the therapeutic doses exerting the maximal efficacy of each enantioselective S-and R-indobufen formulation. S-and R-indobufen were added individually or together to 24 plasma samples from drug-nave healthy subjects, generating 892 samples containing randomly selected concentrations of the drugs of 0-128 mg/L. Collageninduced platelet aggregation in platelet-rich plasma was determined using a Chrono-log Lumi-Aggregometer. Inhibitory sigmoid I max model adequately described the anti-platelet effect. The S-form was more potent, whereas the R-form showed less inter-individual variation. No significant interaction was observed between the two enantiomers. The anti-platelet effect of multiple treatments with 200 mg indobufen twice daily doses was predicted in the simulation study, and the effect of S-or Rindobufen alone at various doses was predicted to define optimal dosing regimen for each enantiomer. Simulation study predicted that 200 mg twice daily administration of S-indobufen alone will produce more treatment effect than S-and R-mixture formulation. S-indobufen produced treatment effect at lower concentration than R-indobufen. However, inter-individual variation of the pharmacodynamic response was smaller in R-indobufen. The present study suggests the optimal doses of R-and S-enantioselective indobufen formulations in terms of treatment efficacy for patients with thromboembolic problems. The proposed methodology in this study can be applied to the develop novel enantio-selective drugs more efficiently.
No takes yet. Share an insight, caveat, or question.
Noh et al. (2018) studied Healthy subjects (n=24). S- and R-indobufen vs. S- and R-mixture formulation was evaluated on Collagen-induced platelet aggregation. Pharmacodynamic modeling predicted that twice daily of S-indobufen alone produces a greater anti-platelet effect than the S- and R-mixture formulation, with S-indobufen being more potent.
Synapse has enriched 10 related papers. Consider them for comparative context: